The expression of ribonucleotide reductase M2 in the carcinogenesis of uterine cervix and its relationship with clinicopathological characteristics and prognosis of cancer patients

Ying Fang Su, Tzu Fan Wu, Jiunn Liang Ko, Hsiu Ting Tsai, Yi Torng Tee, Ming Hsien Chien, Chi Hung Chou, Wea Lung Lin, Hui Ying Low, Ming Yung Chou, Shun Fa Yang, Po Hui Wang

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: To investigate the implication of ribonucleotide reductase M2 (RRM2) in the carcinogenesis of uterine cervix and its relationship with clinicopathological characteristics and prognosis of cancer patients. Methodology and Principal Findings: The impact of RRM2 on cell viability was investigated in SiHa cervical cancer cells after RRM2 knockdown and the addition of cisplatin, which induces inter- and intra-strand DNA crosslinks. RRM2 immunoreactivity was evaluated by semi-quantitative H score among 29 normal, 30 low-grade dysplasia, 30 high-grade dysplasia and 103 invasive cancer tissue specimens of the uterine cervix, using tissue microarrays. RRM2 was then correlated with the clinicopathological variables of cervical cancer and patient survival. A greater toxic effect on cell viability using cisplatin was reflected by the greater reduction in RRM2 protein expression in SiHa cells. The RRM2 expression in cancer tissues was higher than that in high-grade dysplasia, low-grade dysplasia or normal cervical tissues. RRM2 upregulation was correlated with deep stromal invasion, large tumors and parametrial invasion and predicted poor survival. Conclusions: RRM2 is a new molecular marker for the diagnosis and clinical outcomes of cervical cancer. It is involved in cervical carcinogenesis and predicts poor survival, and may be a potential therapeutic target including in cisplatin treatment.

Original languageEnglish
Article numbere91644
JournalPLoS One
Volume9
Issue number3
DOIs
Publication statusPublished - Mar 17 2014
Externally publishedYes

Fingerprint

ribonucleotide reductase
cervix
Cervix Uteri
carcinogenesis
prognosis
Carcinogenesis
neoplasms
Neoplasms
cisplatin
uterine cervical neoplasms
Uterine Cervical Neoplasms
Tissue
Cisplatin
Cells
cell viability
Survival
Cell Survival
ribonucleotide reductase M2
Poisons
Microarrays

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

The expression of ribonucleotide reductase M2 in the carcinogenesis of uterine cervix and its relationship with clinicopathological characteristics and prognosis of cancer patients. / Su, Ying Fang; Wu, Tzu Fan; Ko, Jiunn Liang; Tsai, Hsiu Ting; Tee, Yi Torng; Chien, Ming Hsien; Chou, Chi Hung; Lin, Wea Lung; Low, Hui Ying; Chou, Ming Yung; Yang, Shun Fa; Wang, Po Hui.

In: PLoS One, Vol. 9, No. 3, e91644, 17.03.2014.

Research output: Contribution to journalArticle

Su, Ying Fang ; Wu, Tzu Fan ; Ko, Jiunn Liang ; Tsai, Hsiu Ting ; Tee, Yi Torng ; Chien, Ming Hsien ; Chou, Chi Hung ; Lin, Wea Lung ; Low, Hui Ying ; Chou, Ming Yung ; Yang, Shun Fa ; Wang, Po Hui. / The expression of ribonucleotide reductase M2 in the carcinogenesis of uterine cervix and its relationship with clinicopathological characteristics and prognosis of cancer patients. In: PLoS One. 2014 ; Vol. 9, No. 3.
@article{81a9439d38b64b17986301a6f7368b94,
title = "The expression of ribonucleotide reductase M2 in the carcinogenesis of uterine cervix and its relationship with clinicopathological characteristics and prognosis of cancer patients",
abstract = "Background: To investigate the implication of ribonucleotide reductase M2 (RRM2) in the carcinogenesis of uterine cervix and its relationship with clinicopathological characteristics and prognosis of cancer patients. Methodology and Principal Findings: The impact of RRM2 on cell viability was investigated in SiHa cervical cancer cells after RRM2 knockdown and the addition of cisplatin, which induces inter- and intra-strand DNA crosslinks. RRM2 immunoreactivity was evaluated by semi-quantitative H score among 29 normal, 30 low-grade dysplasia, 30 high-grade dysplasia and 103 invasive cancer tissue specimens of the uterine cervix, using tissue microarrays. RRM2 was then correlated with the clinicopathological variables of cervical cancer and patient survival. A greater toxic effect on cell viability using cisplatin was reflected by the greater reduction in RRM2 protein expression in SiHa cells. The RRM2 expression in cancer tissues was higher than that in high-grade dysplasia, low-grade dysplasia or normal cervical tissues. RRM2 upregulation was correlated with deep stromal invasion, large tumors and parametrial invasion and predicted poor survival. Conclusions: RRM2 is a new molecular marker for the diagnosis and clinical outcomes of cervical cancer. It is involved in cervical carcinogenesis and predicts poor survival, and may be a potential therapeutic target including in cisplatin treatment.",
author = "Su, {Ying Fang} and Wu, {Tzu Fan} and Ko, {Jiunn Liang} and Tsai, {Hsiu Ting} and Tee, {Yi Torng} and Chien, {Ming Hsien} and Chou, {Chi Hung} and Lin, {Wea Lung} and Low, {Hui Ying} and Chou, {Ming Yung} and Yang, {Shun Fa} and Wang, {Po Hui}",
year = "2014",
month = "3",
day = "17",
doi = "10.1371/journal.pone.0091644",
language = "English",
volume = "9",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "3",

}

TY - JOUR

T1 - The expression of ribonucleotide reductase M2 in the carcinogenesis of uterine cervix and its relationship with clinicopathological characteristics and prognosis of cancer patients

AU - Su, Ying Fang

AU - Wu, Tzu Fan

AU - Ko, Jiunn Liang

AU - Tsai, Hsiu Ting

AU - Tee, Yi Torng

AU - Chien, Ming Hsien

AU - Chou, Chi Hung

AU - Lin, Wea Lung

AU - Low, Hui Ying

AU - Chou, Ming Yung

AU - Yang, Shun Fa

AU - Wang, Po Hui

PY - 2014/3/17

Y1 - 2014/3/17

N2 - Background: To investigate the implication of ribonucleotide reductase M2 (RRM2) in the carcinogenesis of uterine cervix and its relationship with clinicopathological characteristics and prognosis of cancer patients. Methodology and Principal Findings: The impact of RRM2 on cell viability was investigated in SiHa cervical cancer cells after RRM2 knockdown and the addition of cisplatin, which induces inter- and intra-strand DNA crosslinks. RRM2 immunoreactivity was evaluated by semi-quantitative H score among 29 normal, 30 low-grade dysplasia, 30 high-grade dysplasia and 103 invasive cancer tissue specimens of the uterine cervix, using tissue microarrays. RRM2 was then correlated with the clinicopathological variables of cervical cancer and patient survival. A greater toxic effect on cell viability using cisplatin was reflected by the greater reduction in RRM2 protein expression in SiHa cells. The RRM2 expression in cancer tissues was higher than that in high-grade dysplasia, low-grade dysplasia or normal cervical tissues. RRM2 upregulation was correlated with deep stromal invasion, large tumors and parametrial invasion and predicted poor survival. Conclusions: RRM2 is a new molecular marker for the diagnosis and clinical outcomes of cervical cancer. It is involved in cervical carcinogenesis and predicts poor survival, and may be a potential therapeutic target including in cisplatin treatment.

AB - Background: To investigate the implication of ribonucleotide reductase M2 (RRM2) in the carcinogenesis of uterine cervix and its relationship with clinicopathological characteristics and prognosis of cancer patients. Methodology and Principal Findings: The impact of RRM2 on cell viability was investigated in SiHa cervical cancer cells after RRM2 knockdown and the addition of cisplatin, which induces inter- and intra-strand DNA crosslinks. RRM2 immunoreactivity was evaluated by semi-quantitative H score among 29 normal, 30 low-grade dysplasia, 30 high-grade dysplasia and 103 invasive cancer tissue specimens of the uterine cervix, using tissue microarrays. RRM2 was then correlated with the clinicopathological variables of cervical cancer and patient survival. A greater toxic effect on cell viability using cisplatin was reflected by the greater reduction in RRM2 protein expression in SiHa cells. The RRM2 expression in cancer tissues was higher than that in high-grade dysplasia, low-grade dysplasia or normal cervical tissues. RRM2 upregulation was correlated with deep stromal invasion, large tumors and parametrial invasion and predicted poor survival. Conclusions: RRM2 is a new molecular marker for the diagnosis and clinical outcomes of cervical cancer. It is involved in cervical carcinogenesis and predicts poor survival, and may be a potential therapeutic target including in cisplatin treatment.

UR - http://www.scopus.com/inward/record.url?scp=84898640423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898640423&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0091644

DO - 10.1371/journal.pone.0091644

M3 - Article

C2 - 24637958

AN - SCOPUS:84898640423

VL - 9

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 3

M1 - e91644

ER -